BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 33539525)

  • 1. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
    Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The transcription factor Olig2 is important for the biology of diffuse intrinsic pontine gliomas.
    Anderson JL; Muraleedharan R; Oatman N; Klotter A; Sengupta S; Waclaw RR; Wu J; Drissi R; Miles L; Raabe EH; Weirauch ML; Fouladi M; Chow LM; Hoffman L; DeWire M; Dasgupta B
    Neuro Oncol; 2017 Aug; 19(8):1068-1078. PubMed ID: 28339768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chaetocin-mediated SUV39H1 inhibition targets stemness and oncogenic networks of diffuse midline gliomas and synergizes with ONC201.
    Xin DE; Liao Y; Rao R; Ogurek S; Sengupta S; Xin M; Bayat AE; Seibel WL; Graham RT; Koschmann C; Lu QR
    Neuro Oncol; 2024 Apr; 26(4):735-748. PubMed ID: 38011799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas.
    Kosty J; Lu F; Kupp R; Mehta S; Lu QR
    Cell Cycle; 2017 Sep; 16(18):1654-1660. PubMed ID: 28806136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal Transduction in Diffuse Intrinsic Pontine Glioma.
    Duchatel RJ; Jackson ER; Alvaro F; Nixon B; Hondermarck H; Dun MD
    Proteomics; 2019 Nov; 19(21-22):e1800479. PubMed ID: 31328874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical evaluation of convection-enhanced delivery of liposomal doxorubicin to treat pediatric diffuse intrinsic pontine glioma and thalamic high-grade glioma.
    Sewing ACP; Lagerweij T; van Vuurden DG; Meel MH; Veringa SJE; Carcaboso AM; Gaillard PJ; Peter Vandertop W; Wesseling P; Noske D; Kaspers GJL; Hulleman E
    J Neurosurg Pediatr; 2017 May; 19(5):518-530. PubMed ID: 28291423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP53 wild-type/PPM1D mutant diffuse intrinsic pontine gliomas are sensitive to a MDM2 antagonist.
    Xu C; Liu H; Pirozzi CJ; Chen LH; Greer PK; Diplas BH; Zhang L; Waitkus MS; He Y; Yan H
    Acta Neuropathol Commun; 2021 Nov; 9(1):178. PubMed ID: 34732238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. H3.3 K27M depletion increases differentiation and extends latency of diffuse intrinsic pontine glioma growth in vivo.
    Silveira AB; Kasper LH; Fan Y; Jin H; Wu G; Shaw TI; Zhu X; Larson JD; Easton J; Shao Y; Yergeau DA; Rosencrance C; Boggs K; Rusch MC; Ding L; Zhang J; Finkelstein D; Noyes RM; Russell BL; Xu B; Broniscer A; Wetmore C; Pounds SB; Ellison DW; Zhang J; Baker SJ
    Acta Neuropathol; 2019 Apr; 137(4):637-655. PubMed ID: 30770999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tenascin-C expression contributes to pediatric brainstem glioma tumor phenotype and represents a novel biomarker of disease.
    Qi J; Esfahani DR; Huang T; Ozark P; Bartom E; Hashizume R; Bonner ER; An S; Horbinski CM; James CD; Saratsis AM
    Acta Neuropathol Commun; 2019 May; 7(1):75. PubMed ID: 31092287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A kinome-wide shRNA screen uncovers vaccinia-related kinase 3 (VRK3) as an essential gene for diffuse intrinsic pontine glioma survival.
    Silva-Evangelista C; Barret E; Ménez V; Merlevede J; Kergrohen T; Saccasyn A; Oberlin E; Puget S; Beccaria K; Grill J; Castel D; Debily MA
    Oncogene; 2019 Sep; 38(38):6479-6490. PubMed ID: 31324890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olig2-Dependent Reciprocal Shift in PDGF and EGF Receptor Signaling Regulates Tumor Phenotype and Mitotic Growth in Malignant Glioma.
    Lu F; Chen Y; Zhao C; Wang H; He D; Xu L; Wang J; He X; Deng Y; Lu EE; Liu X; Verma R; Bu H; Drissi R; Fouladi M; Stemmer-Rachamimov AO; Burns D; Xin M; Rubin JB; Bahassi EM; Canoll P; Holland EC; Lu QR
    Cancer Cell; 2016 May; 29(5):669-683. PubMed ID: 27165742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the immune microenvironment of diffuse intrinsic pontine glioma: implications for development of immunotherapy.
    Lieberman NAP; DeGolier K; Kovar HM; Davis A; Hoglund V; Stevens J; Winter C; Deutsch G; Furlan SN; Vitanza NA; Leary SES; Crane CA
    Neuro Oncol; 2019 Jan; 21(1):83-94. PubMed ID: 30169876
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic targeting of transcriptional elongation in diffuse intrinsic pontine glioma.
    Katagi H; Takata N; Aoi Y; Zhang Y; Rendleman EJ; Blyth GT; Eckerdt FD; Tomita Y; Sasaki T; Saratsis AM; Kondo A; Goldman S; Becher OJ; Smith E; Zou L; Shilatifard A; Hashizume R
    Neuro Oncol; 2021 Aug; 23(8):1348-1359. PubMed ID: 33471107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diffuse intrinsic pontine glioma: molecular landscape and emerging therapeutic targets.
    Aziz-Bose R; Monje M
    Curr Opin Oncol; 2019 Nov; 31(6):522-530. PubMed ID: 31464759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Context-dependent tumor-suppressive BMP signaling in diffuse intrinsic pontine glioma regulates stemness through epigenetic regulation of CXXC5.
    Sun Y; Yan K; Wang Y; Xu C; Wang D; Zhou W; Guo S; Han Y; Tang L; Shao Y; Shan S; Zhang QC; Tang Y; Zhang L; Xi Q
    Nat Cancer; 2022 Sep; 3(9):1105-1122. PubMed ID: 35915262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differential Expression of Wilms' Tumor Protein in Diffuse Intrinsic Pontine Glioma.
    Lee S; Kambhampati M; Yadavilli S; Gordish-Dressman H; Santi M; Cruz CR; Packer RJ; Almira-Suarez MI; Hwang EI; Nazarian J
    J Neuropathol Exp Neurol; 2019 May; 78(5):380-388. PubMed ID: 30990879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The emerging role of NG2 in pediatric diffuse intrinsic pontine glioma.
    Yadavilli S; Scafidi J; Becher OJ; Saratsis AM; Hiner RL; Kambhampati M; Mariarita S; MacDonald TJ; Codispoti KE; Magge SN; Jaiswal JK; Packer RJ; Nazarian J
    Oncotarget; 2015 May; 6(14):12141-55. PubMed ID: 25987129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of cancer gene expression identifies repurposed drugs for diffuse intrinsic pontine glioma.
    Zhao G; Newbury P; Ishi Y; Chekalin E; Zeng B; Glicksberg BS; Wen A; Paithankar S; Sasaki T; Suri A; Nazarian J; Pacold ME; Brat DJ; Nicolaides T; Chen B; Hashizume R
    Acta Neuropathol Commun; 2022 Oct; 10(1):150. PubMed ID: 36274161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative multidimensional molecular analyses of pediatric diffuse intrinsic pontine glioma reveals distinct molecular subtypes.
    Saratsis AM; Kambhampati M; Snyder K; Yadavilli S; Devaney JM; Harmon B; Hall J; Raabe EH; An P; Weingart M; Rood BR; Magge SN; MacDonald TJ; Packer RJ; Nazarian J
    Acta Neuropathol; 2014; 127(6):881-95. PubMed ID: 24297113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Laminin-associated integrins mediate Diffuse Intrinsic Pontine Glioma infiltration and therapy response within a neural assembloid model.
    Sinha S; Huang MS; Mikos G; Bedi Y; Soto L; Lensch S; Ayushman M; Bintu L; Bhutani N; Heilshorn SC; Yang F
    Acta Neuropathol Commun; 2024 May; 12(1):71. PubMed ID: 38706008
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.